Insider Selling: Theravance Biopharma (NASDAQ:TBPH) Major Shareholder Sells $4,718,797.33 in Stock

Theravance Biopharma, Inc. (NASDAQ:TBPH) major shareholder Eli Samaha sold 273,871 shares of the stock in a transaction on Monday, June 29th. The shares were sold at an average price of $17.23, for a total transaction of $4,718,797.33. Following the transaction, the insider owned 9,237,279 shares of the company’s stock, valued at $159,158,317.17. This trade represents a 2.88% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Large shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.

Eli Samaha also recently made the following trade(s):

• On Wednesday, July 1st, Eli Samaha sold 37,799 shares of Theravance Biopharma stock. The stock was sold at an average price of $17.00, for a total transaction of $642,583.00.
• On Tuesday, June 30th, Eli Samaha sold 25,027 shares of Theravance Biopharma stock. The stock was sold at an average price of $17.13, for a total transaction of $428,712.51.

Theravance Biopharma Stock Performance

Shares of NASDAQ TBPH opened at $16.93 on Friday. The firm’s 50-day moving average price is $16.58 and its 200-day moving average price is $17.27. The stock has a market capitalization of $872.74 million, a price-to-earnings ratio of 7.70 and a beta of 0.17. Theravance Biopharma, Inc. has a 12-month low of $10.82 and a 12-month high of $21.03.

Theravance Biopharma (NASDAQ:TBPH) last announced its quarterly earnings results on Tuesday, March 31st. The biopharmaceutical company reported ($0.10) EPS for the quarter. The business had revenue of $17.70 million during the quarter. Theravance Biopharma had a net margin of 104.34% and a return on equity of 18.84%. On average, equities analysts predict that Theravance Biopharma, Inc. will post 1.54 EPS for the current fiscal year.

Analyst Ratings Changes

TBPH has been the topic of a number of analyst reports. JonesTrading cut shares of Theravance Biopharma from a “buy” rating to a “hold” rating in a research report on Monday, June 29th. TD Cowen raised their target price on shares of Theravance Biopharma from $13.00 to $15.00 and gave the stock a “hold” rating in a report on Monday, March 23rd. B. Riley Financial lifted their price target on shares of Theravance Biopharma from $14.00 to $17.00 and gave the stock a “neutral” rating in a research note on Tuesday, April 7th. Wall Street Zen lowered Theravance Biopharma from a “buy” rating to a “hold” rating in a research report on Saturday, May 16th. Finally, BTIG Research cut Theravance Biopharma from a “buy” rating to a “neutral” rating in a research note on Monday. One analyst has rated the stock with a Buy rating and seven have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $21.40.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Arrowstreet Capital Limited Partnership purchased a new position in Theravance Biopharma in the 3rd quarter worth about $10,611,000. Pacer Advisors Inc. bought a new stake in Theravance Biopharma during the 4th quarter valued at about $6,342,000. Janus Henderson Group PLC boosted its position in Theravance Biopharma by 214.8% in the 4th quarter. Janus Henderson Group PLC now owns 400,496 shares of the biopharmaceutical company’s stock valued at $7,493,000 after buying an additional 273,288 shares during the period. Two Sigma Investments LP boosted its position in Theravance Biopharma by 1,199.9% in the 3rd quarter. Two Sigma Investments LP now owns 231,272 shares of the biopharmaceutical company’s stock valued at $3,377,000 after buying an additional 213,480 shares during the period. Finally, HRT Financial LP boosted its position in Theravance Biopharma by 892.8% in the 4th quarter. HRT Financial LP now owns 232,852 shares of the biopharmaceutical company’s stock valued at $4,356,000 after buying an additional 209,397 shares during the period. 99.10% of the stock is currently owned by institutional investors.

Theravance Biopharma Company Profile

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.